ReviewLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2021
The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.
Review in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.Hepatology (Baltimore, Md.) · 2025Review
- Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Acute Kidney Injury in Cirrhosis Revisited-Implications in Clinical Practice.Gastro hep advances · 2025Article
- Defining Renal Recovery in Patients With Hepatorenal Syndrome-Acute Kidney Injury: Experience From North American Studies.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2024Article
- Review
- Development and validation of a nomogram for predicting in-hospital death in cirrhotic patients with acute kidney injury.BMC nephrology · 2024Article
- Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate.ACS pharmacology & translational science · 2024Article
- Disparity Among African Americans in Transjugular Intrahepatic Portosystemic Shunt Procedure: A National Inpatient Sample Analysis from 2015 to 2020.Digestive diseases and sciences · 2024Article
- Role of oral Midodrine in preventing hepatorenal syndrome in Child-Turcotte-Pugh class C cirrhotics: a pilot study.Gastroenterology and hepatology from bed to bench · 2024Article
- Improving Outcomes in Hepatorenal Syndrome-Acute Kidney Injury With Early Diagnoses and Implementation of Approved Treatment Regimens.Gastroenterology & hepatology · 2023Article
- Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.Advances in therapy · 2023Article
- Outcomes among patients with hepatorenal syndrome based on hospital teaching and transplant status: Analysis of 159 845 hospitalizations.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation.eGastroenterology · 2023Review
- Improving the Management of Hepatorenal Syndrome-Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm.Gastroenterology & hepatology · 2023Article
- Prediction models combining zonulin, LPS, and LBP predict acute kidney injury and hepatorenal syndrome-acute kidney injury in cirrhotic patients.Scientific reports · 2023Article
- Review
- Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023Review
- Kidney disease in patients with chronic liver disease: Does sex matter?World journal of clinical cases · 2023Review
Corrections and comments
- Erratum issuedErratum.2022
Authors and funding
9 authors.
Funding
Abstract
Acute kidney injury (AKI) in the setting of cirrhosis (hepatorenal syndrome [HRS]-AKI) is a severe and often fatal complication of end-stage liver disease. The goals of treatment are to reverse renal failure and prolong survival in patients who are critically ill. However, interventions have limited efficacy, and mortality rates remain high. In the United States, the mainstay of pharmacologic therapy consists of the off-label use of vasoconstrictive agents in combination with plasma expanders, a strategy that produces modest effects. Liver transplantation is the ultimate solution but is only an option in a minority of patients because contraindications to transplantation are common and organ availability is limited. Renal replacement therapy is a temporary option but is known to confer an extremely poor short-term prognosis in patients with HRS-AKI and at best serves as a bridge to liver transplantation for the minority of patients who are transplantation candidates. The high mortality rate associated with HRS-AKI in the United States is a reflection of the suboptimal standard of care. Improved therapeutic options to treat HRS-AKI are sought. Terlipressin is a drug approved in Europe for treatment of HRS-AKI and supported by recommendations for first-line therapy by some liver societies and experts around the world. This review article will discuss the substantial unmet medical need associated with HRS-AKI and the potential benefits if terlipressin was approved in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.